GlassScriptPhysician profile
Diana Crisan
NPI 1669796009
$2,109.54
in general payments reported to CMS, 2019-2025
26 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $428 · 2020: $70.19 · 2021: $300 · 2022: $770 · 2023: $372 · 2024: $170.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $522 · Education: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $521.55 |
| Education | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $569.49 | 2021-2024 | Ubrelvy, Qulipta, Botox |
| Biogen, INC. | $304.11 | 2019-2023 | Tysabri |
| Ucb, INC. | $260.64 | 2019-2023 | Briviact |
| Biohaven Pharmaceutical Holding Company LTD. | $119.41 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $94.44 | 2021 | |
| Djo, LLC | $86.75 | 2022 | |
| Upsher-Smith Laboratories LLC | $71.14 | 2022 | |
| Pfizer INC. | $65.42 | 2023-2024 | |
| Novartis Pharmaceuticals Corporation | $63.63 | 2019 | |
| Allergan, INC. | $53.36 | 2019-2020 | |
| Kyowa Kirin, INC. | $43.35 | 2022 | |
| Acadia Pharmaceuticals INC | $39.83 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $39.76 | 2023 | Rexulti, Nuedexta |
| Avanir Pharmaceuticals, INC. | $33.67 | 2019 | |
| Lundbeck LLC | $33.07 | 2019-2024 | Vyepti |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avion Pharmaceuticals | $30.95 | 2022 | |
| Amneal Pharmaceuticals LLC | $29.70 | 2023 | Rytary |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $23.02 | 2024 | Rexulti |
| Alexion Pharmaceuticals, INC. | $22.76 | 2022 | |
| Argenx US, INC. | $21.50 | 2023 | Vyvgart |
| Lilly USA, LLC | $21.46 | 2019 | |
| Csl Behring | $20.00 | 2023 | Kcentra |
| Celgene Corporation | $19.47 | 2021 | |
| Currax Pharmaceuticals LLC | $16.17 | 2023 | Nexletol, Onzetra Xsail, Nexlizet |
| Livanova USA, INC. | $13.25 | 2019 | |
| Ge Healthcare | $13.19 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Diana Crisan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.